ACTINIUM PHARMACEUTICALS, INC. Investment Income, Interest
ACTINIUM PHARMACEUTICALS, INC. (ATNM) reported Investment Income, Interest of $336.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-07
- ACTINIUM PHARMACEUTICALS, INC. investment income, interest for the quarter ending 2026-06-30 was $336.00K, a 46.24% decline year-over-year.
- ACTINIUM PHARMACEUTICALS, INC. investment income, interest for the quarter ending 2026-03-31 was $381.00K, a 45.57% decline year-over-year.
- ACTINIUM PHARMACEUTICALS, INC. investment income, interest for the quarter ending 2025-12-31 was $474.00K, a 44.43% decline year-over-year.
- ACTINIUM PHARMACEUTICALS, INC. investment income, interest for the quarter ending 2025-09-30 was $561.00K, a 45.69% decline year-over-year.
- ACTINIUM PHARMACEUTICALS, INC. investment income, interest for fiscal 2025 was $2.36M, a 39.14% decline from fiscal 2024.
- ACTINIUM PHARMACEUTICALS, INC. investment income, interest for fiscal 2024 was $3.88M, a 25.02% increase from fiscal 2023.
- ACTINIUM PHARMACEUTICALS, INC. investment income, interest for fiscal 2023 was $3.10M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $336.00K 10-Q · filed 2026-08-07 | $717.00K 10-Q · filed 2026-08-07 | $1.19M derived: sum of 3 quarters · filed 2026-08-07 | $1.75M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $381.00K 10-Q · filed 2026-05-08 | $855.00K derived: sum of 2 quarters · filed 2026-05-08 | $1.42M derived: sum of 3 quarters · filed 2026-05-08 | $2.04M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $474.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.03M derived: sum of 2 quarters · filed 2026-03-30 | $1.66M derived: sum of 3 quarters · filed 2026-08-07 | $2.36M 10-K · filed 2026-03-30 |
| 2025-09-30 | $561.00K 10-Q · filed 2025-11-14 | $1.19M derived: sum of 2 quarters · filed 2026-08-07 | $1.89M 10-Q · filed 2025-11-14 | $2.74M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $625.00K 10-Q · filed 2026-08-07 | $1.32M 10-Q · filed 2026-08-07 | $2.18M derived: sum of 3 quarters · filed 2026-08-07 | $3.21M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $700.00K 10-Q · filed 2026-05-08 | $1.55M derived: sum of 2 quarters · filed 2026-05-08 | $2.59M derived: sum of 3 quarters · filed 2026-05-08 | $3.65M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $853.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.89M derived: sum of 2 quarters · filed 2026-03-30 | $2.95M derived: sum of 3 quarters · filed 2026-03-30 | $3.88M 10-K · filed 2026-03-30 |
| 2024-09-30 | $1.03M 10-Q · filed 2025-11-14 | $2.10M derived: sum of 2 quarters · filed 2025-11-14 | $3.02M 10-Q · filed 2025-11-14 | $4.04M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $1.06M 10-Q · filed 2025-08-08 | $1.99M 10-Q · filed 2025-08-08 | $3.01M derived: sum of 3 quarters · filed 2025-08-08 | $4.09M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $927.00K 10-Q · filed 2025-05-09 | $1.95M derived: sum of 2 quarters · filed 2025-05-09 | $3.02M derived: sum of 3 quarters · filed 2025-05-09 | $3.48M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $2.09M derived: sum of 2 quarters · filed 2025-03-31 | $2.56M derived: sum of 3 quarters · filed 2025-03-31 | $3.10M 10-K · filed 2025-03-31 |
| 2023-09-30 | $1.07M 10-Q · filed 2024-11-14 | $1.54M derived: sum of 2 quarters · filed 2024-11-14 | $2.08M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $461.00K 10-Q · filed 2024-08-05 | $1.01M 10-Q · filed 2024-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |